Loading financial data...

Dianthus Therapeutics, Inc. /DE/ (DNTH) Financial Statements | Global Financial Data

Dianthus Therapeutics, Inc. /DE/

DNTHSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1690585

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$6.2M	$2.8M	—	—	—
Research and Development Expense	$83.1M	$32.8M	$29.4M	$46.8M	$50.6M
Operating Expenses	$108.1M	$51.0M	$36.1M	$74.7M	$78.7M
Operating Income (Loss)	-$101.9M	-$48.2M	-$29.7M	-$74.7M	-$78.7M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	$16.9M	$4.6M	$1.2M	—	—
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$374.0M	$179.4M	$83.1M	$189.9M	$161.6M
Assets, Current	$280.9M	$177.5M	$82.0M	$180.7M	$151.5M
Cash and Cash Equivalents, at Carrying Value	$22.8M	$132.3M	$15.4M	$131.7M	$58.2M
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	$294.0K	$4.7M	—	—
Liabilities	$21.5M	$10.5M	$9.5M	$17.3M	$17.7M
Liabilities, Current	$18.5M	$9.6M	$8.2M	$10.9M	$11.4M
Accounts Payable, Current	$4.6M	$2.6M	$1.2M	$3.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$78.2M	-$36.9M	-$29.1M	-$59.5M	-$64.0M
Net Cash Provided by (Used in) Investing Activities	-$286.8M	$20.3M	-$59.8M	$43.4M	-$10.6M
Net Cash Provided by (Used in) Financing Activities	$255.6M	$133.6M	$96.7M	$89.6M	$67.7M
Payments to Acquire Property, Plant, and Equipment	—	—	—	$1.3M	$400.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)